REMEDIUM

In this paper, it was carried out a comprehensive study of the positions of innovative drugs in the Russian pharmaceutical market. Authors identified key barriers for developers of original drugs to receive marketing authorization in Russia. They analyzed share of drugs with new active ingredients in the total number of authorized drugs over 10 years, as well as the role of domestic developers. The leading role of transnational pharmaceutical corporations in the introduction of original drugs to the Russian market have been shown.In accordance with the presented data, brief recommendations have been given for improving the regulatory framework in the field of the development and marketing authorization of innovative drugs.

It looks like the moment of truth will come in the Russian pharmaceutical retail in the coming year after several years of relatively stable development and several waves of feverish demand this year: next year may become a period of the most severe crisis, against which all the current challenges with the introduction of the marking system will seem a mere trifle.

Broad-spectrum antibiotics are used to treat various infectious diseases affecting the digestive tract, the respiratory and genitourinary systems. This group is one of the most numerous among medicinal products. There are currently more than 100 different active substances on the market that are classified as antibiotics. Considering the drug forms and dosages, the number of drugs exceeds 1,700 names.

Nebulized therapy is one of the most reliable and affordable respiratory treatments for patients of all ages. Meanwhile, despite the clear advantages of nebulized therapy and the increasing recognition that it is gaining, serious disagreements have arisen concerning the feasibility of the use of nebulizers due to the risk of coronavirus infection during the COVID-19 pandemic. We tried to go further into the matter.

The article reviews the evidence for an association between non-alcoholic fatty liver disease (NAFLD) and multiple cardiometabolic disorders, including ischemic stroke, insulin resistance, arterial hypertension, dyslipidemia, chronic kidney disease and cardiac arrhythmias and outlines the mechanisms that underpin this relationship. The role of ursodeoxycholic acid, a drug with pleiotropic properties, in the treatment of NAFLD has been shown.

Introduction. Earlier, the comparative analysis of the commercial and investment activities of the companies that play the key roles in the investment processes in the Russian pharmaceutical industry and operate within the four main business models (biotechnological, generic, specialized pharmaceutical companies, active pharmaceutical ingredient (API) manufacturers) has been conducted. No full assessment of the companies’ activities is conceivable without a financial analysis of their activities to identify the risks of investment activities.Objective of the study. A detailed comparative analysis of the financial standing of domestic pharmaceutical manufacturers operating within the selected business models for further identification of potential financial risks for investors. Research procedure and article structure. Analysis of RAS statements (forms 1 and 2) of 72 over 500 million revenue companies grouped together as selectedbusiness models for the period from 2015 to 2019.Results. The researchers provided a detailed description of the commercial activities of domestic pharmaceutical companies within the business models under consideration. The companies within various business models showed positive revenue growth rates over the past five years. All business models demonstrate consistently high business profitability and a significant share of own capital in the asset profile.Conclusion. The results of the study show the stable financial standing of the pharmaceutical companies within various business models. The biotechnology sector companies that are the most attractive for investments have the highest quality financial standing. The specialized and generic companies show similar consistently strong performance. API manufacturers that the companies with relatively small revenues are actively developing and are attractive to restrained budget investors.

The analysis of pharmaceutical enterprises is performed using the data of the state statistical reporting of the industry enterprises. According to Rosstat, the quantum index by type of economic activity with code 21. 2: “Manufacture of drug products and materials used for medical purposes” for the first half of the year was at the level of 115.8% compared to the same period of the previous year, and 161.2% compared to code 21.1: “Manufacture of pharmaceutical substances”.

Производство медицинской продукции за 9 месяцев 2020 года Импорт ГЛС в Россию по итогам 1-го полугодия 2020 года Экспорт ГЛС из России по итогам1-го полугодия 2020 года Фармацевтическая реклама ЛП и БАДв российских СМИ в октябре 2020 года